Immuron joins academia for C. Difficile therapeutics

Australian biotechnology firm Immuron (ASX: IMC) has entered into a collaboration agreement with Australia’s Monash University to develop a product or products that will be aimed at both prevention and treatment of Clostridium difficile infections.

The therapeutic will be based on Immuron’s hyper-immune colostrum platform technology, with its proven safety, particularly in the form of the company’s traveller’s diarrhea drug Travelan.

C. difficile infections have become a major medical problem especially in hospitals and long-term care facilities because the bacteria produce toxins that cause inflammation of the colon, causing severe diarrhoea and, in serious cases, death. An estimated 28,000 people die each year from these infections in the USA alone.